23311_lores.jpg

In an effort to protect populations with limited access to healthcare from coronaviruses and other infectious diseases, EDJEN BIOTECH is using novel, state-of-the-art technology to design vaccines adapted for distribution in the most challenging environments.

EDJEN BIOTECH has a legacy of over two decades of scientific research conducted by a highly talented team who are dedicated to characterizing peptide-induced immune responses and creating peptide-based vaccines.

EDJEN BIOTECH is partnering with the most recognized republic health organizations to bring first in class vaccine solution worldwide.

 

EDJEN BIOTECH has successfully identified immunologically relevant peptide libraries for multiple viral pathogens with highly conserved epitopes, and robust cellular and humoral response has been demonstrated for some targets based on a fully synthetic peptide-based platform and proprietary formulation technology.

We are collaborating with the multiple research and public health organizations to develop and commercialize novel vaccine candidates.